With GERD paying the price, ineffective esophageal motility treatment market to Rise
As per a report available on XploreMR, the global ineffective esophageal motility treatment market will witness an exponentiation between 2020 and 2030.
The global ineffective esophageal motility treatment market is being driven by patients opting for minimally-invasive surgical options. Ineffective esophageal motility treatment implies usage of fundoplication devices along with reflux management systems. Besides, technological advancements like recreation of barrier function, remodeling of tissue using RF energy, and stimulation of radiofrequency for LES (lower esophageal muscles) are expected to upscale the ineffective esophageal motility treatment market.
What’s inside the ineffective esophageal motility treatment market?
The present scenario is such that prevalence of gastroesophageal reflux disease (GERD) is increasing incomparably. This could be reasoned with advanced age, abdominal obesity, and increased use on the part of tobacco. The WGO (World Gastroenterology Organization) states that in North America around 26% of the entire population is affected with GERD. The percentage is close to 6% in the Asia-Pacific.
Intake of antacids and PPI drugs also falls in the category of ineffective esophageal motility treatment. It has been observed that gastroesphageal disorders occur after crossing 40. Lower income countries prefer OTC medications in place of minimally-invasive surgeries, mainly because of ease in production and low-cost materials being available. On these grounds, Lupin Pharmaceuticals did launch Prilosec’s generic version in the year 2015. A year before, the same version was launched by Glenmark.
The outbreak of Covid-19 has resulted in restrictions in travel due to partial/total lockdowns being imposed all over. The healthcare sector has been in a fix, as the priorities have shifted from usual treatments to devising means to combat covid-19. For the time being, people have reduced their visits to hospitals for ineffective esophageal motility treatment. It could be inferred that the market is witnessing a short-term slowdown, but expected to bounce back by mid-2021, especially when concrete measures in the form of Covid-19 vaccine come up.
The global ineffective esophageal motility treatment market comprises North America (Canada, US), Eastern Europe (Russia and Poland), Western Europe (Luxembourg, The Netherlands, Belgium, Nordic countries, Italy, Spain, France, UK, Germany), Asia-Pacific (New Zealand, Australia, ASEAN, Japan, India, China), MEA (North Africa, Southern Africa, GCC), and Latin America (Chile, Peru, Brazil, Mexico, and others).
North America and Europe stand first and second respectively herein. This could be credited to increase in the obese population coupled with rise in the cases of GERD. Plus, in regions like South Asia and East Asia, there is an increase in prevalence of dysphagia, burning chest pain, and achalasia.
The key players are basically focusing on launching new-fangled and advanced treatment products. On these grounds, LINX reflux management device’s advanced version is “LINX”. It is used to facilitate transoral incision-less fundoplication process, which forms as one of the basic lines of treatment for GERD.
Besides, Olympus Corporation has its advanced version of esophagoscopes, which have certainly upscaled the treatment curve on the part of GERD.
The other players in the ineffective esophageal motility treatment market include Mylan Pharmaceutical, MediGus Ltd., Torax Medical, Johnson & Johnson, Medtronic plc, AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc., bayer AG, Pfizer Inc., Bausch Health Companies Inc., LABORIE, Mederi Therapeutics, Inc., Becton, Dickinson and Company (C.R. Bard, Inc.), EndoGastric Solutions, Inc., and Pentax.
Ineffective Esophageal Motility Treatment Market - Scope of the Report
The latest publication by XploreMR on the global ineffective esophageal motility treatment market evaluates the opportunities and current market landscape, and provides detailed analysis and updates about corresponding sections affecting the global ineffective esophageal motility treatment market. The study offers detailed insights on key market dynamics, which include the drivers, restraints, trends, and opportunities in the ineffective esophageal motility treatment market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2020-2030.
Important indicators for the successful growth of the ineffective esophageal motility treatment market are presented in this comprehensive report, including year-on-year (Y-o-Y) growth analysis of the market and compounded annual growth rate (CAGR), which are described in an exhaustive way in XploreMR's research. This research study can support readers to know the demand for ineffective esophageal motility treatment and quantitative development opportunities during the study period.
The research is beneficial for shareholders in the ineffective esophageal motility treatment market, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the ineffective esophageal motility treatment market. The insights and wisdom presented in XploreMR’s study can be leveraged by shareholders in the ineffective esophageal motility treatment market, industry experts, investors, researchers, and reporters, as well as business enthusiasts.
Market statistics as well as information linked to macro- as well as micro-economic variables affecting the business scenario in the Ineffective esophageal motility treatment market are also included in the current study. Depending on potential developments in the ineffective esophageal motility treatment market, substantive insights are also encountered in this report. Additionally, by virtue of the data submitted in this ineffective esophageal motility treatment market report, minor companies and new entrants can make suitable company choices to achieve traction in the ineffective esophageal motility treatment market.
Key Segments of Ineffective Esophageal Motility Treatment Market
XploreMR’s study on the ineffective esophageal motility treatment market offers information divided into four important segments — product, indication, end user, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
Key Questions Answered in XploreMR’s Ineffective Esophageal Motility Treatment Market Report
- Which regions will continue to remain the most profitable regional markets for ineffective esophageal motility treatment market players?
- Which factors will induce a change in the demand for ineffective esophageal motility treatment during the assessment period?
- How will changing trends impact the ineffective esophageal motility treatment market?
- How can market players capture the low-hanging opportunities in the ineffective esophageal motility treatment in developed regions?
- What are the winning strategies of stakeholders in the ineffective esophageal motility treatment market to upscale their position in this landscape?
- What are the restraints that investors need to be aware of and might tackle while investing in the ineffective esophageal motility treatment market?
- What are the developmental trends in ineffective esophageal motility treatment sectors that will impact the market?
- How can businesses in the ineffective esophageal motility treatment market avail the growth opportunities in developed and emerging sectors?
Ineffective Esophageal Motility Treatment Market: Research Methodology
In XploreMR’s study, a unique research methodology is utilized to conduct extensive research on the growth of the ineffective esophageal motility treatment market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure accuracy and reliability of the conclusions.
Secondary resources referred to by analysts during the production of the ineffective esophageal motility treatment market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.
Comprehensive information acquired from primary and secondary resources acts as a validation from companies in the ineffective esophageal motility treatment market, and makes XploreMR’s projections on the growth prospects of the ineffective esophageal motility treatment market more accurate and reliable.
Global Market Study on Ineffective Esophageal Motility Treatment: Increasing Prevalence of GERD and Obesity to Propel Market GrowthBuy Now
Custom Market Research Services
xploreMR offers custom market reserch services that help clients to get information on their business scenario required where syndicated solutions are not enough
Why Choose XploreMR
Our analysts go above and beyond to answer your specific queries. We are with you throughout the entire journey – from initial discussion to post-purchase.
Country-wise Analysis & Forecasting
As we track markets at country-level, we are able to offer hard-to-find market intelligence in both developed and emerging countries.
High Quality At Competitive Pricing
We believe high quality market research shouldn’t be out of reach for businesses. Our competitively-priced market research reports ensure businesses of all sizes have access to quality information
A recent market study published by XploreMR on the sleep apnea diagnostic systems market offers global industry analysis for 2016-2020 & opportunity assessment for 2021–2031. The s ...